前沿生物：公司早在数年前便聚焦小核酸赛道，核心是看好该领域的临床应用与市场前景

Core Viewpoint - The company has focused on the small nucleic acid sector for several years, driven by the clinical application and market potential of this field [1] Group 1: Clinical Value and Competitive Advantage - The company emphasizes the potential clinical value and differentiated competitiveness of its products, assessing efficacy, safety, and dosing frequency compared to existing and in-development drugs [1] - Market space and unmet clinical needs are also considered during pipeline project evaluations [1] Group 2: Internal Capabilities and Experience - The company has over 20 years of experience in peptide drug development, particularly in long-acting delivery technologies, which can be leveraged in small nucleic acid drug development [1] - A successful development of Aikening has established a comprehensive R&D system from early project initiation to non-clinical research, ensuring efficient execution and understanding of the entire new drug development process [1] Group 3: Future Expectations - The company looks forward to sharing new progress and results in the small nucleic acid field with investors in the near future [1]